NUREXONE BIOLOGIC INC

0.4486

0.0000

Volume:- -

Turnover:- -

Market Cap:41.29M

PE:-5.21

High:0.4486

Open:0.4486

Low:0.4486

Close:0.4486

52wk High:0.8000

52wk Low:0.4086

Shares:92.05M

Float Shares:90.53M

Volume Ratio:1.85

T/O Rate:- -

Dividend:- -

Dividend Rate:- -

EPS(TTM):-0.0860

EPS(LYR):-0.0814

ROE:-298.06%

ROA:-129.23%

PB:28.34

PE(LYR):-5.51

Loading ...

Overview Company News Filings

Concept

No relevant data is available

Capital Flow

Inflow:

Outflow:

News

NurExone Biologic Appoints Eyal Gabbai to Board

Reuters

·

Jan 31

Press Release: NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results

Dow Jones

·

Aug 28, 2025

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers | Global Stocks, Options & Futures Trading App","description":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","keywords":"tiger brokers,tiger trade,tiger brokers singapore,broker online,stock trading in singapore,share trading singapore,brokerage firm singapore,trading app,stock broker singapore,stock trading platforms,trading account","social":{"ogDescription":"Tiger Brokers, one-stop investment in US stocks, SGX stocks, HK stocks, A-shares & other global assets. One of the best stock trading platforms in Singapore.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/stock/NRXBF"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"SGP","license":"TBSG","edition":"fundamental","symbol":"NRXBF","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NRXBF\",,,,,undefined,":{"symbol":"NRXBF","market":"US","secType":"STK","nameCN":"NUREXONE BIOLOGIC INC","latestPrice":0.448607,"timestamp":1775160000000,"preClose":0.448607,"halted":0,"volume":0,"delay":15,"changeRate":0,"floatShares":90529200,"shares":92045848,"eps":-0.086028,"marketStatus":"Market Closed","change":0,"latestTime":"04-02 16:00:00 EDT Delay","open":0.448607,"high":0.448607,"low":0.448607,"amount":0,"amplitude":0,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"otc":true,"ttmEps":-0.086028,"tradingStatus":0,"nextMarketStatus":{"tag":"Pre-Mkt","tradingStatus":1,"beginTime":1775462400000},"marketStatusCode":7,"adr":0,"exchange":"OTCQB","adjPreClose":0.448607,"volumeRatio":1.854753501391468},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"NRXBF\",,,,,undefined,":{"symbol":"NRXBF","floatShares":90529200,"roa":"-129.23%","roe":"-298.06%","lyrEps":-0.081368,"volumeRatio":1.854753501391468,"shares":92045848,"dividePrice":0,"high":0.448607,"amplitude":0,"preClose":0.448607,"low":0.448607,"week52Low":0.40855,"pbRate":"28.34","week52High":0.8,"institutionHeld":0,"latestPrice":0.448607,"eps":-0.086028,"divideRate":0,"volume":0,"delay":15,"ttmEps":-0.086028,"open":0.448607,"prevYearClose":0.4889,"prevWeekClose":0.4193,"prevMonthClose":0.4299,"prevQuarterClose":0.4299,"fiveDayClose":0.4193,"twentyDayClose":0.4592,"sixtyDayClose":0.4559},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/NRXBF\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"NRXBF\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"NRXBF\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"NRXBF\",pageSize:4,pageCount:1,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2607213280","title":"NurExone Biologic Appoints Eyal Gabbai to Board","url":"https://stock-news.laohu8.com/highlight/detail?id=2607213280","media":"Reuters","labels":["executive"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2607213280?lang=en_us&edition=fundamental","pubTime":"2026-01-31 05:03","pubTimestamp":1769806991,"startTime":"0","endTime":"0","summary":"NurExone Biologic Inc. has appointed Eyal Gabbai to its Board of Directors, replacing Dr. Gadi Riesenfeld, who has resigned from the Board. Dr. Riesenfeld will continue to support the company as a member of its Scientific Advisory Board.Disclaimer: This news brief was created by Public Technologies  using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. NurExone Biologic Inc. published the original content used to generate this news brief via GlobeNewswire  on January 30, 2026, and is solely responsible for the information contained therein.","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20260130:nNDL1L9fw3:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"executive","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["LU0672654240.SGD","LU1037948541.HKD","IE00BWXC8680.SGD","IE00B2B36J28.USD","LU1674673691.USD","IE00B7SZLL34.SGD","LU0310800379.SGD","LU0528227936.USD","LU2028103732.USD","LU0820561818.USD","SG9999014005.SGD","LU1037948897.HKD","LU2362541273.HKD","LU1003077747.HKD","LU1548497426.USD","IE00BFSS8Q28.SGD","LU0345770993.USD","LU2271345857.HKD","LU1064131342.USD","LU0316494557.USD","IE00BJJMRZ35.SGD","LU0048584097.USD","LU0128525689.USD","LU2491049909.HKD","BK4588","LU0738911758.USD","LU1854104046.USD","LU1066051811.HKD","LU1267930490.SGD","LU1988902786.USD","IE00BJT1NW94.SGD","LU1718418525.SGD","IE00BKVL7J92.USD","LU0432979614.USD","IE00BFSS7M15.SGD","LU2361045086.USD","SG9999014898.SGD","IE00BN29S564.USD","LU1074936037.SGD","LU1061106388.HKD","SGXZ57979304.SGD","IE0004445015.USD","IE00B1BXHZ80.USD","IE00BKPKM429.USD","LU0354030511.USD","LU0079474960.USD","LU2362541513.USD","IE00B894F039.SGD","LU1854103824.USD","LU2112291526.USD","LU2089283258.USD","IE00BZ1G4Q59.USD","LU0820561909.HKD","SG9999001176.SGD","LU1720051108.HKD","LU0052756011.USD","LU2264538146.SGD","UNHG","LU0912757837.SGD","LU1720051017.SGD","SG9999014039.USD","LU1119994496.HKD","IE00BGHQF748.EUR","LU1778281490.HKD","LU0158827948.USD","LU1291159041.SGD","LU0965509010.AUD","IE00B4R5TH58.HKD","LU0238689110.USD","IE00BJJMRY28.SGD","LU0203345920.USD","LU0882574055.USD","LU1069347547.HKD","LU0211326755.USD","LU2552382215.SGD","IE00B7KXQ091.USD","LU0077335932.USD","LU0861579265.USD","SG9999002232.USD","IE00B19Z8W00.USD","LU0545039389.USD","BK4585","LU1066053197.SGD","LU0128525929.USD","IE0005OL40V9.USD","SG9999014021.USD","LU0149725797.USD","LU0342679015.USD","LU2211815571.USD","IE00BFTCPJ56.SGD","LU0310799852.SGD","LU0417517546.SGD","LU0965508806.USD","SG9999018857.SGD","LU1814569148.SGD","SGXZ31699556.SGD","LU0058720904.USD","LU0211327993.USD","LU0289739699.SGD","LU1267930227.SGD","BK4534","IE00B4JS1V06.HKD","LU0456855351.SGD","NRXBF","LU2468319806.SGD","IE000M9KFDE8.USD","IE00B3QW5Z07.USD","LU0557290698.USD","LU1057294990.SGD","IE00B19Z3B42.SGD","IE00B19Z9505.USD","LU1791710582.SGD","LU0097036916.USD","LU2125154778.USD","LU2360032135.SGD","LU0965509101.SGD","SG9999018865.SGD","LU0965509283.SGD","LU0203347892.USD","LU2491050154.USD","BK4154","SG9999014906.USD","LU2361044949.HKD","LU0708994859.HKD","BK4581","LU1914381329.SGD","BK4533","LU0353189680.USD","IE00B19Z3581.USD","IE00BFXG1179.USD","LU0353189763.USD","LU2095319765.USD","LU2347655156.SGD","LU0251132253.USD","LU0354030438.USD","LU0109391861.USD","BK4532","LU1791710400.SGD","LU0107464264.USD","LU2244417387.USD","LU2461242641.AUD","LU1674673428.USD","LU0949170772.SGD","IE00B64PRP62.GBP","LU0029864427.USD","LU2552382058.USD","LU1267930573.SGD","LU1934455863.HKD","SG9999001176.USD","LU1934455277.USD","LU0820562030.AUD","IE00B1XK9C88.USD","LU1323610961.USD","IE0009355771.USD","LU2125154935.USD","LU1084165304.USD","LU1153585028.USD","SGXZ99366536.SGD","LU2089284900.SGD","LU1267930730.SGD","BK4566","LU0094547139.USD","LU2089984988.USD","IE00B19Z9Z06.USD","LU2362540622.SGD","SG9999014880.SGD","LU0345770308.USD","LU2023251221.USD","LU2087625088.SGD","IE00BZ9MQY76.HKD","LU0211328371.USD","LU0114720955.EUR","IE00B775H168.HKD","LU0496365809.HKD","LU1670627923.USD","LU0187121727.USD","UNHW","SG9999014914.USD","SG9999013999.USD","IE00BSNM7G36.USD","LU0053666078.USD","LU0198837287.USD","LU0211326839.USD","LU2210149790.SGD","LU2236285917.USD","LU1066051225.USD","LU2491050071.SGD","SG9999014013.SGD","IE00B19Z8X17.USD","LU1496350502.SGD","LU0823416689.USD","LU2242649171.HKD","LU2279689827.SGD","LU2552382132.HKD","SG9999002224.SGD","LU0011850046.USD","LU0122379950.USD","LU0787776722.HKD","IE00BJJMRX11.SGD","IE0002141913.USD","LU0234572021.USD","LU0689472784.USD","LU0310800965.SGD","LU0943347566.SGD","SGXZ81514606.USD","LU1506573853.SGD","LU1934455194.USD","SGXZ51526630.SGD","LU0553294199.USD","LU1551013425.SGD","LU0256863811.USD","LU0661504455.SGD","SG9999017495.SGD","LU1670628061.USD","IE0004445239.USD","LU0708995401.HKD","LU0976567544.SGD","LU1035773651.USD","LU1732799900.SGD","LU1983299246.USD","LU0158827781.USD","BK4112","LU0320765059.SGD","LU2324357040.USD","LU2361044865.SGD","LU1066051498.USD","LU0314104364.USD","LU1732800096.USD","LU0266013472.USD","LU1261432733.SGD","LU0683600562.USD","LU0795875086.SGD","IE00B19Z9P08.USD","LU2210150020.SGD","LU0795875169.SGD","LU1023059063.AUD","LU2133065610.SGD","LU1989771016.USD","IE0002270589.USD","LU2357305700.SGD","LU1551013342.USD","LU2111349929.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2562703410","title":"Press Release: NurExone Biologic Inc. Announces Second Quarter 2025 Financial Results","url":"https://stock-news.laohu8.com/highlight/detail?id=2562703410","media":"Dow Jones","labels":["dataReport"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2562703410?lang=en_us&edition=fundamental","pubTime":"2025-08-28 20:15","pubTimestamp":1756383300,"startTime":"0","endTime":"0","summary":"TORONTO and HAIFA, Israel, Aug. 28, 2025  -- NurExone Biologic Inc.    , a preclinical-stage biotechnology company pioneering exosome-based therapies for central nervous system injuries, is pleased to announce its financial results for the second quarter ended June 30, 2025 , and provide a corporate update on its recent activities and upcoming milestones.The Company's full set of unaudited condensed interim consolidated financial statements for the six months ended June 30, 2025, and accompanying management's discussion and analysis can be accessed by visiting the Company's website at www.nurexone.com and its SEDAR+ profile at www.sedarplus.ca.-- C$2.3 million raised through Private Placement: On April 10, 2025,NurExone completed a non-brokered private placement of 3,543,238 units.  at a price of C$0.65 per April 2025 Unit,raising gross proceeds of approximately C$2.3 million (the \"April 2025. Offering\"). Each April 2025 Unit consisted of  one common share in the. capital of the Compan","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://dowjonesnews.com/newdjn/logon.aspx?AL=N","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"dataReport","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK4139","NRXBF"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/NRXBF\",params:#limit:6,delay:false,,,undefined,":[]}}